Metabolic tumor burden as a prognostic indicator after neoadjuvant chemotherapy in pancreatic cancer
Woohyung Lee(Ulsan College), Song Cheol Kim(Ulsan College), Ki Byung Song(Ulsan College), Minkyu Sung(Ulsan College), Minyoung Oh(Ulsan College), Dae Wook Hwang(Asan Medical Center), Kyu‐pyo Kim(Ulsan College), Baek‐Yeol Ryoo(Asan Medical Center), Kwangpyo Hong(Ulsan College), Jae Seung Kim(Ulsan College), Bong Jun Kwak(Ulsan College), Eunsung Jun(Asan Medical Center), Yejong Park(Ulsan College), Changhoon Yoo(Ulsan College), Jae Hoon Lee(Ulsan College), Jae Ho Jeong(Ulsan College), Heung-Moon Chang(Ulsan College), Jung Bok Lee(Asan Medical Center), Inkeun Park(Asan Medical Center)
Cited by 15
Related Papers
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k
Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers
|Proceedings of the National Academy of Sciences|2017|577
Futibatinib for <i>FGFR2</i> -Rearranged Intrahepatic Cholangiocarcinoma
|New England Journal of Medicine|2023|530